Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 1.00 |
| ▸ | CDK2 | P24941 | 6/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 3/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 3/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | PRKACG | P22612 | 1/20 | 0.53 |
| ▸ | PRKACB | P22694 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611365 | 1.00 | CDK1 (1.00) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL24239234 | 0.88 | CDK1 (0.78) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL28083712 | 0.86 | CDK1 (0.76) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL784159 | 0.84 | CDK2 (0.73) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL16080845 | 0.84 | CDK2 (0.73) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL24236940 | 0.84 | CDK1 (0.72) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL21539217 | 0.83 | CDK1 (0.71) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL24235899 | 0.83 | CDK2 (0.71) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL21540017 | 0.83 | CDK1 (0.71) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL23641811 | 0.83 | CDK1 (0.71) | CDK1CDK2CCNB1CCNE1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-3728283-B1 | 3'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7238795-B2 | Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CDK1 428/4885CDK2 1244/4885CCNB1 1651/4885 |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | DUT, PNP, RNGTT | CDK1 1838/4885CDK2 1677/4885CCNB1 2441/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | CDK1 3802/4885CDK2 4017/4885CCNB1 4735/4885 |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | CDK1 455/4885CDK2 540/4885CCNB1 1941/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | CDK1 114/4885CDK2 223/4885CCNB1 634/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CDK1 3079/4885CDK2 1336/4885CCNB1 3030/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | CDK1 4245/4885CDK2 2615/4885CCNB1 3934/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | CDK1 2787/4885CDK2 3025/4885CCNB1 3587/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | CDK1 114/4885CDK2 223/4885CCNB1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.